Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
CHASE WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director William J. Chase received an equity award of 5,491 deferred stock units (DSUs) under the company’s 2024 Equity Incentive Plan. Each DSU represents the right to receive one share of common stock upon settlement.
The DSUs vest in full on the earlier of June 18, 2027 or the date of the next annual meeting of stockholders, subject to Chase’s continued service through the vesting date. Following this award, Chase directly holds 42,702 shares of GRAIL common stock.
GRAIL, Inc. director Steven Mizell received an equity award of 5,491 deferred stock units (DSUs) under the company’s 2024 Equity Incentive Plan, in lieu of 5,491 restricted stock units. The DSUs vest in full on June 18, 2027 or on the date of the next annual stockholder meeting, subject to continued service, and will settle into an equal number of common shares. After this grant, Mizell directly holds 42,562 shares. This is a compensation-related, non‑market acquisition rather than an open‑market share purchase.
SUMME GREGORY L reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director Gregory L. Summe received an equity award of 5,491 deferred stock units under the company’s 2024 Equity Incentive Plan. Each unit represents one share of common stock to be delivered at settlement.
The DSUs vest in full on the earlier of June 18, 2027 or the next annual stockholder meeting, subject to his continued service. After this grant, Summe directly holds 45,245 shares of GRAIL common stock.
Krevans Sarah reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. reported that director Sarah Krevans received an equity award of 5,491 deferred stock units (DSUs) under the company’s 2024 Equity Incentive Plan. The DSUs vest in full on the earlier of June 18, 2027 or the next annual stockholder meeting, subject to continued service. Each DSU will settle into one share of common stock, and following this grant she holds 42,628 common shares directly.
GRAIL, Inc. held its Annual Meeting of Stockholders on June 18, 2026, with a quorum of 35,076,394 shares present out of 42,916,593 shares entitled to vote as of the April 22, 2026 record date.
Stockholders elected Class II directors Sarah Krevans and Steven Mizell to serve until the 2029 annual meeting. Krevans received 18,929,398 votes for and 2,972,804 withheld, while Mizell received 16,998,081 votes for and 4,904,121 withheld, in each case with 13,174,192 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,611,318 votes for, 57,682 against, and 407,394 abstentions.
GRAIL, Inc.'s Chief Growth Officer Andrew John Partridge reported an automatic sale of common stock tied to equity compensation. On the transaction date, an executing broker sold 1,491 shares in open-market trades at a weighted average price of $61.08 per share to cover withholding taxes when an award vested and shares were delivered. After these sell-to-cover transactions, Partridge directly held 163,738 shares of GRAIL common stock, indicating this was a small, tax-related disposition relative to his remaining stake.
Ofman Joshua J. reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director and Chief Executive Officer Joshua J. Ofman received equity compensation in the form of common‑stock–settled restricted stock units. He was granted 27,901 shares and 3,154 shares of common stock-equivalent awards, not purchased on the open market. These RSUs vest in four substantially equal annual installments beginning on May 31, 2027, contingent on continued service, and will be settled in common stock upon vesting. Following these awards, he directly holds 402,271 shares of GRAIL common stock.
Gr-al Holdings, Inc. files a Form 144 reporting a proposed sale of 2,914 shares. The filing states these shares were acquired upon vesting of restricted stock units awarded under the issuer's equity incentive plans on 06/03/2026.
The notice also lists prior reported dispositions by Andrew Partridge of 1,445 shares on 03/09/2026 (value $69,201.05) and 35,240 shares on 04/08/2026 (value $1,759,180.80). Shares outstanding are shown as 43,073,334 as of 06/03/2026.
GRAIL, Inc. disclosed the initial holdings of Chief Growth Officer Andrew John Partridge on a Form 3. He directly owns 165,229 shares of GRAIL common stock. This filing records his starting equity position as an officer, without reporting any recent stock purchases or sales.
GRAIL, Inc. updated the employment terms for its new Chief Executive Officer, Dr. Joshua Ofman, and showcased detailed clinical data for its Galleri multi‑cancer early detection test. The amended offer letter makes Dr. Ofman the principal executive officer as of June 1, 2026, with an annual base salary of $800,000 and a variable compensation plan target equal to 100% of salary from that date. He will receive restricted stock units valued at $2,000,000, vesting over four years, and significant severance protections, including up to 24 months of salary, 200% of target bonus, full equity acceleration, and extended healthcare benefits if he is terminated without cause or resigns for good reason in connection with a change in control.
The accompanying investor presentation from ASCO 2026 highlights results from the NHS‑Galleri and PATHFINDER 2 trials, covering roughly 180,000 participants. Adding Galleri to standard screening reduced Stage IV cancers for 12 deadly cancer types by more than 20% in incident screening rounds, increased early‑stage (Stage I/II) detections by about 16%, and quadrupled screening‑detected cancers versus standard screening alone. The test showed positive predictive value around 52–60%, a false positive rate below 0.5%, and high accuracy in predicting cancer signal origin, with no serious study‑related adverse events reported.